Editas Medicine (United States)

Recent papers from Editas Medicine (United States)

1. A Transformative in Vivo Crispr Gene Editing Medicine Upregulates LDLR and Meaningfully Reduces LDL-C in Non-Human PrimatesAtherosclerosis · 2026
2. Industry Perspective on Translational and Clinical Pharmacology Aspects of Viral-based Gene Therapies and Vaccines—Key Considerations and Learnings From Approved ProductsThe AAPS Journal · 2026
3. Neurodivergent perspectives in geoscience: Reflections from the development of paleontology museum educational materialsJournal of Geoscience Education · 2026
4. Mechanistic basis for improved activity of Engineered AsCas12aCommunications Biology · 2026
5. CRISPR-Cas12a gene editing of the HBG1/2 promoters leads to sustained normalization of total hemoglobin and increased fetal hemoglobin in patients with severe sickle cell disease: Updated Results from the RUBY trialBlood · 2025
6. KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)Molecular Cancer Therapeutics · 2025
7. Nonclinical evaluation of HBG1/2 and BCL11A as genome-editing targets for the treatment of β-hemoglobinopathiesBlood Advances · 2024
8. Abstract PO2-16-03: ESR1 genomic alterations (GAs) and coexistent putative resistance alterations in comprehensive genomic profiling (CGP) of metastatic breast cancer (MBC)Cancer Research · 2024
9. Abstract PO2-16-05: ESR1 mutations (ESR1mut) in HR(+)HER2(-)patients with metastatic breast cancer (MBC): prevalence along treatment course and predictive value for endocrine therapy (ET) resistance in real-world practiceCancer Research · 2024
10. Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue ConfirmationClinical Cancer Research · 2024
11. Abstract A017: An analysis of 13 independently performed assays to measure homologous recombination deficiency using 90 freshly extracted high grade serous ovarian tumors: findings from the friends of cancer research hrd harmonization projectCancer Research · 2024
12. Twelve-month Natural History Study of Centrosomal Protein 290 (CEP290)-associated Inherited Retinal DegenerationOphthalmology Science · 2024
13. AsCas12a Gene Editing of HBG1/2 Promoters with Edit-301 Results in Early and Sustained Normalization of Hemoglobin and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease and Transfusion-Dependent Beta-ThalassemiaBiology of Blood and Marrow Transplantation · 2024
14. S264: Edit-301 Shows Promising Preliminary Safety and Efficacy Results in the Phase I/Ii Clinical Trial (Ruby) of Patients With Severe Sickle Cell Disease Using Highly Specific and Efficient Ascas12a EnzymeHemaSphere · 2023
15. AAV Gene Augmentation of Truncated Complement Factor H Differentially Rescues Ocular Complement Dysregulation in a Mouse ModelInvestigative Ophthalmology & Visual Science · 2023
16. Gene therapy for cross-correction of somatic organs and the CNS in mucopolysaccharidosis II in rodents and non-human primatesMolecular Therapy — Methods & Clinical Development · 2023
17. Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 TrialClinical Cancer Research · 2022
18. Bi‐layered living cellular construct resulted in greater healing in an alloxan‐induced diabetic porcine modelInternational Wound Journal · 2022
19. Mapping the genetic landscape of DNA double-strand break repairCell · 2021
20. Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4+ T-cellsNature Communications · 2021